Peregrine Pharmaceuticals Inc - PPHM - reported preliminary results related with its Bavituximab from a randomized Phase II trial showing a 50% improvement in overall tumor response rates in non-small cell lung cancer patients.

Peregrine Pharmaceuticals Inc - PPHM - reported preliminary results related with its Bavituximab from a randomized Phase II trial showing a 50% improvement in overall tumor response rates in non-small cell lung cancer patients. ( moins )